Brought to you by 
Schering-Plough licenses asthma drugs from Chiroscience
Oct 1997
Executive Summary
Schering-Plough has licensed the exclusive, worldwide rights to Chiroscience's PDE IV inhibitors (potential orally-available asthma and other inflammatory disease treatments) for up to $38mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering-Plough licenses asthma drugs from Chiroscience
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice